Cleanascite™ Facilitates Selective Lipid Depletion to Identify Tumor-Suppressive Oxylipin in Breast Cancer Study
A pre-print study published by researchers at the University of Utah entitled “Lean breast adipocytes secrete an oxylipin that suppresses breast cancer via ferroptosis” has uncovered a linoleic acid-derived oxylipin, 9S-HODE, secreted by lean breast.

Press Release


Cleanascite™ Facilitates Selective Lipid Depletion to Identify Tumor-Suppressive Oxylipin in Breast Cancer Study


MONMOUTH JUNCTION, NJ, August 25, 2025– A pre-print study published by researchers at the University of Utah entitled “Lean breast adipocytes secrete an oxylipin that suppresses breast cancer via ferroptosis” has uncovered a linoleic acid-derived oxylipin, 9S-HODE, secreted by lean breast adipocytes, which suppresses breast cancer growth through the induction of ferroptosis. The study, investigating the mechanistic basis of obesity-associated breast cancer progression, leveraged Cleanascite™, BSG’s proprietary lipid clearance reagent, to dissect lipid-mediated signaling within the adipocyte secretome. 


Using differential lipid depletion methodologies, researchers demonstrated that Cleanascite™ did not abrogate the growth suppression effect of lean adipocyte secretome, thereby narrowing the active lipid candidates. This selectivity was crucial in subsequent QTOF LC-MS lipidomics and targeted QQQ LC-MS/MS analyses, which identified 9S-HODE as the key lipid species responsible for inducing ferroptotic cell death selectively in breast cancer cells, while sparing normal mammary epithelial cells. The study highlights Cleanascite™’s utility for precision lipidomic workflows, supporting translational research aimed at restoring tumor-suppressive lipid profiles in obesity-linked cancers.


“While the study looked at other lipid binding methods, only Cleanascite™ was able to differentiate oxylipins from other lipid structures and that feature was essential to the study’s result.” stated Dr. Swapan Roy, President and Founder of Biotech Support Group. “It is possible that micelles derived from oxylipins differ from micelles derived from other endogenous lipids, and that Cleanascite™ displayed a differential affinity, with less bias towards the oxylipin structures, necessary to isolate the study’s most important target 9S-HODE.”


For additional product details, visit:
Cleanascite™ Lipid Removal Reagent

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: mkuruc@biotechsupportgroup.com

Keywords: Cleanascite™, lipid depletion, adipocyte secretome, breast cancer, tumor microenvironment, lipidomics, oxylipins